Anaplastic large cell lymphoma

Disease ID:1215
Name:Anaplastic large cell lymphoma
Associated with:0 targets
0 immuno targets immuno relevant
1 immuno ligands
A non-Hodgkin lymphoma involving aberrant T-cells encompassing at least 4 different clinical entities that all reveal the presence of large pleomorphic cells expressing CD30 and T-cell markers under histological examination.
Database Links
Disease Ontology: DOID:0050744


No target related data available for Anaplastic large cell lymphoma


Ligand Approved Immuno References Clinical comments
brentuximab vedotin  [ FDA (2011), EMA (2012) ( ]
Clinical Use: Brentuximab vedotin is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma [2] and systemic anaplastic large cell lymphoma. Several clinical trials are evaluating the combination of brentuximab vedotin with immune checkpoint inhibitors, to assess any synergistic effects as a result of dual targeting. Checkpoint inhibitors being investigated in this way include nivolumab and pembrolizumab (both anti-PD-1), and ipilimumab (anti-CTLA4). Brentuximab vedotin + pembrolizumab (NCT02684292) and brentuximab vedotin + nivolumab (NCT03138499) are both Phase 3 studies in patients with relapsed/refractory classical Hodgkin's lymphoma.

Expanded approvals:
In November 2017, the FDA approved brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, following review of results from the Phase 3 ALCANZA trial (NCT01578499) [1].
Immuno Disease Comments: Approved drug for systemic anaplastic large cell lymphoma, and primary cutaneous ALCL.


Show »

1. FDA. FDA approves Brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma. Accessed on 10/11/2017. Modified on 10/11/2017.,

2. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A et al.. (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet,  [Epub ahead of print]. [PMID:25796459]